ESMO 2025: Oral drug demonstrates promising anti-tumor activity in patients with advanced lung cancer
Lung cancer is the leading cause of cancer-related death worldwide, with up to 4% of non-small cell lung cancer cases having a HER2 gene mutation.
Sevabertinib is an oral drug targeting HER2 mutations that shrinks tumors in advanced lung cancer patients, with minimal side effects.Â
FDA granted priority review for sevabertinib, and results of this study will help inform the decision. Â
BERLIN...
ESMO 2025: Targeted therapy plus radiation or surgery improves outcomes in patients with advanced lung cancer
Lung cancer is the leading cause of cancer-related death worldwide, with non-small cell lung cancer (NSCLC) the most common formÂ
Study reveals how bacteria in tumors drive treatment resistance in cancer
Researchers uncovered a previously unknown way for microbes within tumors to contribute to treatment resistance in certain cancers...